Increased Intraocular Pressure After Ocular Procedure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for increased intraocular pressure after ocular procedure. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
4
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators in Increased Intraocular Pressure After Ocular Procedure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Lavipharm 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating increased intraocular pressure after ocular procedure. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27
2
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Catapres-Tts-1
CLONIDINE
 Lavipharm 4 54 — 2027-04-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8337890 Catapres-Tts-1 formulation 60 2027-04-17
8337890 Catapres-Tts-1 formulation 60 2027-04-17
8623409 Catapres-Tts-1 formulation 48 2031-09-08
8623409 Catapres-Tts-1 formulation 48 2031-09-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8623409 Catapres-Tts-1 formulation 48 2031-09-08
8623409 Catapres-Tts-1 formulation 48 2031-09-08
8337890 Catapres-Tts-1 formulation 60 2027-04-17
8337890 Catapres-Tts-1 formulation 60 2027-04-17

Related